Frenesí por pérdida de peso con Wegovy
September 6, 2023 - El exitoso fármaco para pérdida de peso Wegovy es el nombre comercial de la semaglutida, que imita la acción de una hormona que produce sensación de saciedad, ayudando a que las personas coman menos.
Shares of the Danish drugmaker have soared 40% this year, boosted by skyrocketing demand for its weight-loss drugs Ozempic and Wegovy.
At the close of trading Monday, Novo Nordisk had a market capitalization of 2.96 trillion Danish krone ($428 billion).
Ozempic and Wegovy are drugs developed to treat type 2 diabetes that contain the same active ingredient -- semaglutide, a GLP-1 (glucagon-like peptide 1) -- which clinical trials have shown can help people lose 15% of their body weight after less than 16 months.
On Monday, Novo Nordisk also announced that Wegovy would now be available in the UK “through a controlled and limited launch.”
“This new generation of medicines [has] the potential to be a game-changer,” UK Health and Social Care Minister Steve Barclay posted on social media site X.
Used for long-term weight management, Wegovy’s high cost -- about $1,350 per month in the U.S. -- can make it unaffordable for many patients unless their insurance covers it.
Novo Nordisk has made almost 49 billion Danish krone ($7 billion) in profit over the first six months of this year, up 30% from the same period in 2022.